Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA2302FEB" target="_blank" >RIV/61988987:17110/21:A2302FEB - isvavai.cz</a>
Alternative codes found
RIV/00098892:_____/21:N0000050 RIV/00843989:_____/21:E0109499 RIV/61989592:15110/21:73608719
Result on the web
<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000800866900003" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000800866900003</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1159/000520302" target="_blank" >10.1159/000520302</a>
Alternative languages
Result language
angličtina
Original language name
Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes
Original language description
Background: Various cerebrospinal fluid (CSF) biomarkers are studied in Parkinson's disease (PD) and atypical parkinsonian syndromes (APS). Several studies found reduced 5-hydroxyindoleacetic acid (5-HIAA), the main serotonin metabolite, in PD. There is little evidence regarding its levels in APS. Methods: We measured 5-HIAA in the CSF of 90 PD patients, 16 MSA patients, 26 progressive supranuclear palsy (PSP) patients, 11 corticobasal syndrome (CBS) patients, and 31 controls. We also compared the values in depressed and nondepressed patients. Results: There was a statistically significant difference in CSF 5-HIAA in PD and MSA compared to the control group (median in PD 15.8 mu g/L, in MSA 13.6 mu g/L vs. 24.3 mu g/L in controls; p = 0.0008 in PD, p = 0.006 in MSA). There was no statistically significant difference in CSF 5-HIAA in PSP and CBS compared to the control group (median in PSP 22.7 mu g/L, in CBS 18.7 mu g/L vs. 24.3 mu g/L in controls; p = 1 in both PSP and CBS). CSF 5-HIAA levels were lower in PD patients with depression compared to PD patients without depression (median 8.34 vs. 18.48, p < 0.0001). Conclusions: CSF 5-HIAA is decreased in PD and MSA. The CSF 5-HIAA levels in PSP and CBS did not differ from those of the control group. There was a tendency toward lower CSF 5-HIAA in MSA than in PD; however, the results did not reach statistical significance. These results may be explained by more severe damage of the serotonergic system in synucleinopathies (PD and MSA) than in tauopathies (PSP and CBS). (C) 2021 S. Karger AG, Basel
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neurodegenerative Diseases
ISSN
1660-2854
e-ISSN
—
Volume of the periodical
—
Issue of the periodical within the volume
1-2
Country of publishing house
CH - SWITZERLAND
Number of pages
6
Pages from-to
30-35
UT code for WoS article
000800866900003
EID of the result in the Scopus database
—